Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is well-positioned for growth with strong product candidates, a focus on improving drug delivery to the central nervous system, and a strong financial foundation. The company's promising clinical trials and status as an FDA designated company bode well for their success. With a strong intellectual property portfolio and expected entry into the market in 2030, NeOnc has the potential to make a significant impact in the biopharmaceutical industry.

Bears say

NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company that has promising drug candidates for brain cancer treatment, but faces significant risks and challenges in its development process. While their lead drug NEO100 has shown an exceptional safety profile and promising efficacy data in a Phase 1 trial, its mechanism of action and potential for combination therapies still need to be fully understood and optimized. Additionally, NeOnc has a complex dosing process for its drugs and may face difficulties in clinical trials and commercial markets. The company is young and has relatively limited financial resources, which may hinder its ability to bring its drugs to market quickly.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.